Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $4.14 USD
Change Today +0.09 / 2.22%
Volume 7.9K
BONE On Other Exchanges
As of 8:04 PM 03/27/15 All times are local (Market data is delayed by at least 15 minutes).

bacterin international holdi (BONE) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/31/14 - $8.50
52 Week Low
11/20/14 - $2.19
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

bacterin international holdi (BONE) Related Businessweek News

No Related Businessweek News Found

bacterin international holdi (BONE) Details

Bacterin International Holdings, Inc. develops, manufactures, and markets biologics products in the United States and internationally. The company offers products that are used in various applications, including enhancing fusion in spine surgery, relief of back pain with a facet joint stabilization, promotion of bone growth in foot and ankle surgery, promotion of skull healing, neurosurgery, and regeneration in knee and other joint surgeries. Its products include OsteoSponge, which provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSponge SC, a subchondral bone void filler; OsteoSelect DBM putty, an osteoinductive product used by surgeons as a bone void filler in the extremities and pelvis; and OsteoWrap that wraps around non-union fractures to assist with fusion, and could be used in conjunction with a hardware plate system. The company also provides OsteoLock and BacFast HD facet stabilization dowels that are used to augment spinal procedures; OsteoSTX for posterolateral spine surgery applications, including scoliosis procedures; and hMatrix dermal scaffold, which promotes cellular ingrowth, tissue vascularization, and regeneration. In addition, it processes and sells sports allografts for anterior and posterior cruciate ligament repairs, anterior cruciate ligament reconstruction, and meniscal repair; milled spinal allografts; and traditional allografts for orthopedics, neurology, podiatry, oral/maxillofacial, genitourinary, and plastic/reconstructive applications. Further, the company’s products include 3Demin cortical fibers, 3Demin boats, and 3Demin strips made from cortical bone and primarily used in spine procedures. It markets its products through direct sales, as well as through distributor relationships. Bacterin International Holdings, Inc. is headquartered in Belgrade, Montana.

148 Employees
Last Reported Date: 03/18/15

bacterin international holdi (BONE) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $500.2K
Total Annual Compensation: $153.8K
Chief Financial Officer, Treasurer and Secret...
Total Annual Compensation: $350.0K
Chief Operating Officer
Total Annual Compensation: $338.6K
Chief Scientific Officer
Total Annual Compensation: $271.1K
Compensation as of Fiscal Year 2014.

bacterin international holdi (BONE) Key Developments

Bacterin International Holdings Mulls Acquisitions

Bacterin International Holdings, Inc. (AMEX:BONE) is seeking acquisition. Dan Goldberger, Chief Executive Officer of Bacterin International Holdings, said in Bacterin International Holdings earnings call, "In addition to our own developments, we are evaluating a number of acquisition opportunities that would leverage our regenerative medicine focus and our rapidly growing distribution capability that calls on orthopedic and neurosurgeons.”

Bacterin International Holdings, Inc. Announces Audited Consolidated Earnings Results for the Fourth Quarter and Year Ended December 31, 2014; Provides Earnings Guidance for Full Year 2015; Reports Impairment of Assets

Bacterin International Holdings, Inc. announced audited consolidated earnings results for the fourth quarter and year ended December 31, 2014. For the quarter, the company reported total revenue of $9,081,406 against $8,257,776 a year ago. Loss from operations was $2,490,364 against $3,559,750 a year ago. Net loss from operations before income taxes was $3,302,297 against $4,164,243 a year ago. Net loss was $3,302,297 or $0.49 per basic and diluted share against $4,164,243 or $0.83 per basic and diluted share a year ago. EBITDA was a loss of $1.1 million compared to a loss of $1.6 million for the same period during 2013. For the year, the company reported total revenue of $35,331,812 against $33,073,414 a year ago. Loss from operations was $6,264,729 against $9,007,579 a year ago. Net loss from operations before income taxes was $10,507,869 against $12,693,125 a year ago. Net loss was $10,507,869 or $1.76 per basic and diluted share against $12,693,125 or $2.80 per basic and diluted share a year ago. Net cash used in operating activities was $7,324,059 against $4,892,306 a year ago. Purchases of property and equipment and intangible assets were $299,978 against $623,045 a year ago. EBITDA was a loss of $3.5 million compared to an EBITDA loss of $5.8 million in the prior year. Based on the planned growth of the company's hybrid salesforce, combined with new product launches, the company currently anticipates 2015 full-year revenue to be in the range of $40 million to $42 million compared to $35.3 million reported for 2014. The company is forecasting 61% to 63% gross margin for 2015. For the quarter, the company reported impairment of assets was $912,549 against $728,618 a year ago.

Bacterin International Holdings, Inc. Announces Contract Extension with Novation

Bacterin International Holdings, Inc. announced that it has extended its contract with Novation for an additional year. The extension will allow Bacterin to continue to supply Novation members with OsteoSponge, OsteoSelect DBM Putty, and other proprietary Bacterin allografts. Novation develops and manages competitive contracts with more than 700 suppliers. As a biologic supplier, Bacterin is one of only three companies with a contract for demineralized bone matrix technologies and one of four allograft suppliers.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BONE:US $4.14 USD +0.09

BONE Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Biolase Inc $2.00 USD -0.01
Cardica Inc $0.59 USD -0.01
Stereotaxis Inc $2.08 USD +0.01
Uroplasty Inc $1.30 USD +0.02
Vision Sciences Inc/DE $0.44 USD +0.02
View Industry Companies

Industry Analysis


Industry Average

Valuation BONE Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 0.8x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 0.1x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BACTERIN INTERNATIONAL HOLDI, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at